Skip to content
Open access

Association Between Plasma microRNA Levels and Major Adverse Cardiovascular Events in Participants from an Epidemiological Cohort

Oct 2026 · International Journal of Molecular Sciences · Vol 27, pp. 9221 · 0 citations · 48 references
Medicine

TL;DR

Findings support plasma miRNA profiles as potential MACE biomarkers and all DE miRNAs remain exploratory, although further studies in larger independent populations with cross-validation are required before integration with traditional risk markers to predict future MACE.

Abstract

Circulating microRNAs (miRNAs) are promising biomarkers of cardiovascular disease (CVD) and three-point major adverse cardiovascular events (3P-MACE): CVD death, non-fatal myocardial infarction (MI), and non-fatal stroke. The associations between plasma miRNA levels and 3P-MACE in a prospective cohort from an epidemiological study were evaluated. This nested case–control study included 479 participants: 166 cases with 3P-MACE and 313 controls matched individually for sex, exact baseline age, and region of residence. Median follow-up was 10.4 years [7.0; 11.7]. Total RNA was isolated from EDTA plasma using the miRNeasy Serum/Plasma Advanced Kit. Libraries were prepared with the QIAseq miRNA UDI Library Kit and sequenced on a NextSeq 550 (1 × 75 bp). After adjustment for six and twelve preanalytical and clinical covariates, eleven and five differentially expressed (DE) miRNAs retained significant associations with 3P-MACE or CVD death, respectively. Although these findings support plasma miRNA profiles as potential MACE biomarkers, all DE miRNAs remain exploratory. Further studies in larger independent populations with cross-validation are required before integration with traditional risk markers to predict future MACE.

Read PDF

Similar papers

Open access Oct 2026

Differential associations of cardiorenal-inflammatory markers with incident cardiovascular disease and cancer in the general population

Elevated levels of cardiorenal-inflammatory markers reflect not only risk of cardiovascular disease (CVD), but also of cancer. The objectives of the current study were to examine whether N-terminal pro-B-type natriuretic peptide (NT-proBNP), urinary albumin excretion (UAE) and high-sensitivity C reactive protein...

Y. Yang, T.-F. Kok, M. Maronier et al. · 0 citations
Open access Oct 2026

Inflammation and lipoprotein(a) as predictors of cardiovascular events across baseline risk levels - results from the UK Biobank.

AIMS To determine how high-sensitivity C-reactive protein (hsCRP) and lipoprotein(a) [Lp(a)] predict major adverse cardiovascular events (MACE) across the spectrum of baseline cardiovascular risk. METHODS UK Biobank participants were grouped according to baseline cardiovascular risk. The primary endpoint was first MA...

B. Tucker, Leung-Ong Kwok, Thomas Payne et al. · 0 citations
Review Nov 2026

Abstract 13508: Elevated Plasma miR-92a as a Potential Risk Stratification Biomarker in Patients with Chronic Coronary Syndrome: A 2-Year Follow-Up Study

Introduction: MicroRNAs are emerging biomarkers involved in the regulation of endothelial function andatherosclerotic plaque progression. MicroRNA-92a (miR-92a) downregulates Kruppel-likefactor 2 (KLF2), a key mediator of endothelial homeostasis and atheroprotection.Although elevated miR-92a expression has been link...

Maria Przezdziecka, M. Kowara, Agnieszka Cudnoch-Jędrzejewska · 0 citations
Open access Oct 2026

Interleukin-6 predicts cardiovascular events beyond standard modifiable risk factors in individuals without atherosclerotic cardiovascular disease

Current risk stratification algorithms capture high-risk individuals with classical risk factors or established atherosclerotic cardiovascular disease (ASCVD). However, a clinically relevant proportion of individuals without threshold levels of standard modifiable risk factors (SMuRF) – namely hypertension, dysli...

F. Kahles, B. Kurt, K. Schneider et al. · 0 citations
Open access Nov 2026

A plasma proteomic frailty signature for cardiovascular risk stratification: A multi-cohort study

Background Frailty predicts adverse health outcomes, but its relationship with cardiovascular disease (CVD) requires further validation across diverse populations. The value of a circulating protein signature for cardiovascular risk assessment remains uncertain. Methods We examined frailty–CVD associations in the XiDu2...

Ping-Jing Zheng, Jia-Bo Wu, Xiao-Qing Gu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.